PT Kalbe Farma Tbk. (PTKFF) Research

Indonesia-based pharmaceutical powerhouse, PT Kalbe Farma Tbk., along with its affiliated companies, is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products throughout the country. The organization structures its operations across four primary business units: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers a diverse range of medications, including generic, branded, and licensed drugs such as Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG, which are supplied to hospitals, pharmacies, and drug retailers. Beyond prescription items, its product line includes over-the-counter medicines, energy drinks, ready-to-consume beverages, dietary supplements, and other preventive health products. Furthermore, the company provides specialized nutritional offerings catering to all age groups—from infants and toddlers to children, adolescents, adults, expectant and lactating mothers, and seniors—as well as individuals with particular medical dietary requirements. The firm also extends contract services to other pharmaceutical companies, covering clinical study management, bioavailability/bioequivalence studies, and analytical services. Its activities further include the provision of animal health products and the operation of the Mitrasana Clinics healthcare service network. Additionally, PT Kalbe Farma Tbk. offers health screening services, acts as an agent and representative for biotechnology products, distributes various consumer goods, medical equipment, cosmetics, and other trade items. It also trades in medical and laboratory apparatus and supplies, raw materials for pharmaceutical production, and consumable products essential for hemodialysis therapy, while also providing advertising services. Founded in 1966, PT Kalbe Farma Tbk. is headquartered in Jakarta, Indonesia.

Open PT Kalbe Farma Tbk. (PTKFF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.